| Literature DB >> 31320940 |
Swathi Satish1, Maithri Tharmavaram1, Deepak Rawtani1.
Abstract
The arena of biomedical science has long been in quest of innovative mediums for diagnostic and therapeutic applications. The latest being the use of nanomaterials for such applications, thereby giving rise to the branch of nanomedicine. Halloysite nanotubes (HNTs) are naturally occurring tubular clay nanomaterials, made of aluminosilicate kaolin sheets rolled several times. The aluminol and siloxane groups on the surface of HNT facilitate the formation of hydrogen bonding with the biomaterials onto its surface. These properties render HNT pivotal in diverse range of applications, such as in environmental sciences, waste-water treatment, dye removal, nanoelectronics and fabrication of nanocomposites, catalytic studies, as glass coatings or anticorrosive coatings, in cosmetics, as flame retardants, stimuli response, and forensic sciences. The specific properties of HNT also lead to numerous applications in biomedicine and nanomedicine, namely drug delivery, gene delivery, tissue engineering, cancer and stem cells isolation, and bioimaging. In this review, recent developments in the use of HNT for various nanomedicinal applications have been discussed.Entities:
Keywords: Halloysite nanotube; cancer therapy; drug delivery; nanobiomedicine; tissue engineering
Year: 2019 PMID: 31320940 PMCID: PMC6628522 DOI: 10.1177/1849543519863625
Source DB: PubMed Journal: Nanobiomedicine (Rij) ISSN: 1849-5435
Figure 1.Structure of halloysite nanotube.[6]
Figure 2.Characterization of HNT: (a) TEM, (b) SEM, (c) XRD, and (d) FTIR.[8,9] HNT: halloysite nanotubes; TEM: transmission electron microscopy; SEM: scanning electron microscopy; XRD: X-ray diffraction.
Figure 3.Applications of halloysite nanotubes in biomedicine.
Figure 4.Types of drugs loaded into halloysite nanotubes.
Applications of halloysite nanotubes in drug delivery.
| S. no. | Drug | HNT and modifier | Advantage | Drug loading (wt%) | Site of drug loading | Release rate (wt%/mg g−1 h−1) | Release kinetics model | Application | References |
|---|---|---|---|---|---|---|---|---|---|
| 1. | DS | Sodium alginate/hydroxyapatite/HNT nanocomposite hydrogel beads |
Cumulative release behavior | 74.63 ± 1.65 | Lumen | 9.19 mg g−1 h−1 | — | Controlled drug delivery |
[ |
| 2. | IBU | APTES-modified HNT |
Slow release due to strong affinity through electrostatic attraction | 14.8 | Lumen and partially on outer surface | — | Korsmeyer–Peppas model | Controlled release of drug |
[ |
| 3. | Aspirin | APTES modified or natural HNT |
Increased amount of aspirin loading | 11.98 | Lumen pores | — | Higuchi kinetic model | Controlled release of drug |
[ |
| 4. | Amoxicillin, brilliant green, chlorhexidine doxycycline, gentamicin sulfate, iodine, and potassium calvulanate | HNT-PCL scaffolds |
Enhancers of structural integrity Inhibition of bacterial growth | — | Lumen | — | — | Sutures and surgical dressings |
[ |
| 5. | Thermo-responsive curcumin | Poly( |
Brownian diffusion and electrophoretic mobility dependent on temperature | 3.6 | Lumen | Approximately 10 pH 6.8 | — | Biocompatible thermo sensitive materials for controlled release |
[ |
| 6. | Curcumin | Dual responsive nanocarrier |
Covalent linking through GSH- or pH-responsive bonds. Good stability and retaining of antioxidant property of curcumin. | 2.9 wt% | Covalently linked to outer surface | Approximately 25% in acidic pH | Power fit equation | Controlled release of prodrug for anticancer therapy |
[ |
| 7. | RAB | — |
Prevents comparative acidic degradation of RAB in stomach | 8.355 ± 1.542 | Lumen | 94% up to 24 h | — | Increased bioavailability and sustained drug release |
[ |
| 8. | Paclitaxel | HNT coated with pH-responsive polymer poly(methacrylic acid-co-methyl methacrylate) |
Hindered release in acidic pH and increased release in basic pH | 7.5 ± 0.5 | Lumen | 40% at 120 h | Korsmeyer–Peppas model | Sustained release for anticancer therapy |
[ |
| 9. | Doxorubicin | MPTS-HNT |
Folate-mediated targeting and redox-responsive drug delivery. Promotes apoptosis of cancer cells in vitro | 14.8 | Outer surface | 40% at 79 h | — | Anticancer therapy |
[ |
| 10. | CIP | APTES functionalized HNT |
Increased drug loading. Decrease in iron absorption after complexation with CIP | 70% ± 1.7% | Outer surface | 92% ± 3% | — | Increased bioavailability of the drug upon administration |
[ |
| 11. | CPT | Folic acid –conjugated chitosan oligosaccharide-magnetic HNTs |
Stronger cell growth inhibition against colon cancer cell. | 227.10 mg g−1 | Lumen | Sustained release up to 60 h | — | Tumor-targeted drug delivery |
[ |
| 12. | Chlorogenic acid, ibuprofen, and salicylic acid | Dendrimer functionalized HNT |
Carrier for low molecular size drugs No toxicity to living organisms | 123.16 mg g−1 (chlorogenic acid); 182.72 mg g−1 (IBU); 39.52 mg g−1 (salicylic acid) | Outer surface | — | — | Controlled release of drugs |
[ |
| 13. | Sodium salicylate | Acid treatment and composite polymer halloysite modification |
Enlarged the lumen of HNT. Delayed the release of the drug. | — | Lumen | — | Zero order | Controlled release of drugs. |
[ |
| 14. | Quercetin | PEG amine-grafted HNT |
Improved drug loading | 278.36 mg g−1 | Outer surface | — | — | Controlled release with antitumor targeted drug delivered |
[ |
DS: diclofenac sodium; IBU: ibuprofen; PCL: poly-e-caprolactone; RAB: rabeprazol sodium; MPTS: (3-mercaptopropyl) trimethoxysilane; CIP: ciprofloxacin; CPT: camptothecin; PEG: polyethylene glycol; ATC: anaplastic thyroid cancer; APTES: aminopropyltriethoxysilane; HNT: halloysite nanotube.
Figure 5.Properties and types of scaffolds for tissue engineering.
Figure 6.Halloysite nanotube in cancer therapy.
Halloysite nanotube in cancer therapy.
| S. no | Drug loaded | Modification of HNT | Cell line | Target | Reference |
|---|---|---|---|---|---|
| 1. | Doxorubicin | FA and magnetite nanoparticles grafted onto HNT | HeLa | Anticancer therapeutics |
[ |
| 2. | Resveratrol | LbL polyectrolyte multilayer functionalization of HNT | MCF-7 | Breast cancer |
[ |
| 3. | Curcumin | Trizolium salts functionalization | Several cell lines | ATC, hepatic cancer |
[ |
| 4. | Silibinin and quercetin | HNT-amphiphilic cyclodextrin Hybrids | Human anaplastic thyroid cancer cell lines 8505C | Thyroid cancer |
[ |
| 5. | Atorvastatin and celecoxib | HNT encapsulated in pH-responsive hydroxypropyl methylcellulose acetate succinate polymer | Caco-2 | Colon cancer |
[ |
| 6. | Curcumin | Chitosan-grafted HNT | HepG2 | Anticancer therapeutics |
[ |
| 7. | Doxorubicin | Chitosan oligosaccharide modified HNT | MCF-7 | Breast cancer |
[ |
| 8. | Curcumin | AuNP in lumen and chitosan-coated HNT | MCF-7 | Anticancer drug delivery |
[ |
FA: folic acid; HNT: halloysite nanotube; AuNP: gold nanoparticle; LbL: layer-by-layer.